About us Contacts Drug interactions: 390 212
Drug search by name

Lidocaine IV Solution and Zykadia

Determining the interaction of Lidocaine IV Solution and Zykadia and the possibility of their joint administration.

Check result:
Lidocaine IV Solution <> Zykadia
Relevance: 17.07.2022 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Consumer information for this interaction is not currently available.GENERALLY AVOID: Coadministration with ceritinib may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 2C9 and/or 3A4. In vitro data suggest that ceritinib may inhibit these isoenzymes at clinical concentrations. In vivo pharmacokinetic data are not available. MANAGEMENT: Concomitant use of ceritinib and sensitive CYP450 2C9/3A4 substrates or substrates with narrow therapeutic ranges should generally be avoided. These drugs include alfentanil, colchicine, cyclosporine, ergot derivatives, fentanyl, lovastatin, simvastatin, oral midazolam, triazolam, phenytoin, pimozide, quinidine, sildenafil, sirolimus, tacrolimus, and warfarin. If coadministration is required, dosage reductions for the CYP450 2C9 or 3A4 substrates should be considered. References Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0 "Product Information. Zykadia (ceritinib)." Novartis Pharmaceuticals, East Hanover, NJ.

Professional:

GENERALLY AVOID: Coadministration with ceritinib may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 2C9 and/or 3A4. In vitro data suggest that ceritinib may inhibit these isoenzymes at clinical concentrations. In vivo pharmacokinetic data are not available.

MANAGEMENT: Concomitant use of ceritinib and sensitive CYP450 2C9/3A4 substrates or substrates with narrow therapeutic ranges should generally be avoided. These drugs include alfentanil, colchicine, cyclosporine, ergot derivatives, fentanyl, lovastatin, simvastatin, oral midazolam, triazolam, phenytoin, pimozide, quinidine, sildenafil, sirolimus, tacrolimus, and warfarin. If coadministration is required, dosage reductions for the CYP450 2C9 or 3A4 substrates should be considered.

References
  • Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  • "Product Information. Zykadia (ceritinib)." Novartis Pharmaceuticals, East Hanover, NJ.
Lidocaine IV Solution

Generic Name: lidocaine

Brand name: UAD Caine, Xylocaine HCl, Xylocaine-MPF, Lidoject 1, Xylocaine Dental Cartridges, Lidoject 2, Xylocaine Duo-Trach Kit, Xylocaine HCl For Spinal, L-Caine, Dilocaine, Nervocaine, Truxacaine, Anestacaine

Synonyms: Lidocaine injection, Lidocaine (Systemic)

Zykadia

Generic Name: ceritinib

Brand name: Zykadia

Synonyms: n.a.

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.

Interaction with food and lifestyle
Disease interaction